BIO Europe
Flexible solutions for biotech companies at every value inflection point
Expertise for Every Modality in Early Development
Certara offers new, emerging and VC-backed biotech companies a modern and data driven approach to drug development. Starting with the end in mind, Certara’s cross functional experts will support your team to further your scientific insights, optimize resources, and de-risk your therapy development journey.
Expertise for every modality:
- Small molecules, Biologics (monoclonal antibodies, ADCs)
- Complex biologics (Bispecific Abs, siRNA, oligonucleotides)
- Cell and Gene Therapies, Vaccines, Drug-device combos and Devices
Certara Strategy Early Development Solutions
후보물질 선정부터 제1상까지 전 단계에 걸친 전문적 지원
후보물질 선정 단계에서 제1상 프로그램으로의 성공적인 전환을 위해서는 신약 개발에 대한 풍부한 경험과 전문지식이 필요합니다. 의약품 개발에는 높은 비용과 실패율 및 긴 일정으로 인해 야기되는 고유한 과제가 수반됩니다. 따라서 초기 개발 단계 전반에서 후보물질에 대한 최적의 전략을 채택하는 것이 중요합니다. 초기 단계의 성공이 자금 조달 및 파트너십 기회를 확보하고 이후 단계에서 성과를 이어갈 수 있는 토대가 되기 때문입니다.
Strategic Partnerships for Early Development Success
Are you spending too much time managing multiple consultants/vendors, telling them what to do, and hoping your timelines don’t slip? Certara offers a strategic partnership that streamlines your early development work, allowing you to focus on what matters most.
Certara’s solutions:
- A full team of cross-functional virtual drug developers
- Relationships with individual experts who become an integrated part of your team
- Strategic recommendations from a collaborative partner invested in your success
Certara played a key role in Biohaven’s approval of Nurtec, contributing to the company’s acquisition by Pfizer for almost $12B. Check out a video testimonial here.
Our comprehensive services have recently helped clients:
- Achieve an accelerate approval in pediatric oncology
- Avoid the costly expense of entering Phase 1 with a starting dose that was too low
- Reach significant milestones in development and regulatory approval
Additional Resources